Global Pre-Menstrual Syndrome Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Pre-Menstrual Syndrome Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Analgesics (Pain Killers)
  • 1.4.3 Oral Contraceptive Pills (OCPs)
  • 1.4.4 Gonadotropin-Releasing Hormone (GnRH)
  • 1.4.5 Antidepressants
  • 1.4.6 Ovarian Suppressors
  • 1.4.7 Diuretics
  • 1.4.8 Benzodiazepines
• 1.5 Market by Application
  • 1.5.1 Global Pre-Menstrual Syndrome Market Share by Application (2019-2025)
  • 1.5.2 Hospitals
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Pre-Menstrual Syndrome Market Size
• 2.2 Pre-Menstrual Syndrome Growth Trends by Regions
  • 2.2.1 Pre-Menstrual Syndrome Market Size by Regions (2019-2025)
  • 2.2.2 Pre-Menstrual Syndrome Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Pre-Menstrual Syndrome Market Size by by Players
  • 3.1.1 Global Pre-Menstrual Syndrome Revenue by by Players (2014-2019)
  • 3.1.2 Global Pre-Menstrual Syndrome Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Pre-Menstrual Syndrome Market Concentration Ratio (CR5 and HHI)
• 3.2 Pre-Menstrual Syndrome Key Players Head office and Area Served
• 3.3 Key Players Pre-Menstrual Syndrome Product/Solution/Service
• 3.4 Date of Enter into Pre-Menstrual Syndrome Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Pre-Menstrual Syndrome Market Size by Type (2014-2019)
• 4.2 Global Pre-Menstrual Syndrome Market Size by Application (2014-2019)

5 North America

• 5.1 North America Pre-Menstrual Syndrome Market Size (2014-2019)
• 5.2 Pre-Menstrual Syndrome Key Players in North America
• 5.3 North America Pre-Menstrual Syndrome Market Size by Type
• 5.4 North America Pre-Menstrual Syndrome Market Size by Application

6 Europe

• 6.1 Europe Pre-Menstrual Syndrome Market Size (2014-2019)
• 6.2 Pre-Menstrual Syndrome Key Players in Europe
• 6.3 Europe Pre-Menstrual Syndrome Market Size by Type
• 6.4 Europe Pre-Menstrual Syndrome Market Size by Application

7 China

• 7.1 China Pre-Menstrual Syndrome Market Size (2014-2019)
• 7.2 Pre-Menstrual Syndrome Key Players in China
• 7.3 China Pre-Menstrual Syndrome Market Size by Type
• 7.4 China Pre-Menstrual Syndrome Market Size by Application

8 Japan

• 8.1 Japan Pre-Menstrual Syndrome Market Size (2014-2019)
• 8.2 Pre-Menstrual Syndrome Key Players in Japan
• 8.3 Japan Pre-Menstrual Syndrome Market Size by Type
• 8.4 Japan Pre-Menstrual Syndrome Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Pre-Menstrual Syndrome Market Size (2014-2019)
• 9.2 Pre-Menstrual Syndrome Key Players in Southeast Asia
• 9.3 Southeast Asia Pre-Menstrual Syndrome Market Size by Type
• 9.4 Southeast Asia Pre-Menstrual Syndrome Market Size by Application

10 India

• 10.1 India Pre-Menstrual Syndrome Market Size (2014-2019)
• 10.2 Pre-Menstrual Syndrome Key Players in India
• 10.3 India Pre-Menstrual Syndrome Market Size by Type
• 10.4 India Pre-Menstrual Syndrome Market Size by Application

11 Central & South America

• 11.1 Central & South America Pre-Menstrual Syndrome Market Size (2014-2019)
• 11.2 Pre-Menstrual Syndrome Key Players in Central & South America
• 11.3 Central & South America Pre-Menstrual Syndrome Market Size by Type
• 11.4 Central & South America Pre-Menstrual Syndrome Market Size by Application

12 International Players Profiles

• 12.1 Alva-Amco Pharmacal Cos., Inc.
  • 12.1.1 Alva-Amco Pharmacal Cos., Inc. Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Pre-Menstrual Syndrome Introduction
  • 12.1.4 Alva-Amco Pharmacal Cos., Inc. Revenue in Pre-Menstrual Syndrome Business (2014-2019))
  • 12.1.5 Alva-Amco Pharmacal Cos., Inc. Recent Development
• 12.2 Bayer, Inc.
  • 12.2.1 Bayer, Inc. Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Pre-Menstrual Syndrome Introduction
  • 12.2.4 Bayer, Inc. Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.2.5 Bayer, Inc. Recent Development
• 12.3 Chattem, Inc. (Sanofi)
  • 12.3.1 Chattem, Inc. (Sanofi) Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Pre-Menstrual Syndrome Introduction
  • 12.3.4 Chattem, Inc. (Sanofi) Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.3.5 Chattem, Inc. (Sanofi) Recent Development
• 12.4 DEKK-TEC, Inc.
  • 12.4.1 DEKK-TEC, Inc. Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Pre-Menstrual Syndrome Introduction
  • 12.4.4 DEKK-TEC, Inc. Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.4.5 DEKK-TEC, Inc. Recent Development
• 12.5 G. R. Lane Health Products Ltd
  • 12.5.1 G. R. Lane Health Products Ltd Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Pre-Menstrual Syndrome Introduction
  • 12.5.4 G. R. Lane Health Products Ltd Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.5.5 G. R. Lane Health Products Ltd Recent Development
• 12.6 McNeil Consumer Healthcare
  • 12.6.1 McNeil Consumer Healthcare Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Pre-Menstrual Syndrome Introduction
  • 12.6.4 McNeil Consumer Healthcare Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.6.5 McNeil Consumer Healthcare Recent Development
• 12.7 MetP Pharma AG
  • 12.7.1 MetP Pharma AG Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Pre-Menstrual Syndrome Introduction
  • 12.7.4 MetP Pharma AG Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.7.5 MetP Pharma AG Recent Development
• 12.8 Pherin Pharmaceuticals, Inc.
  • 12.8.1 Pherin Pharmaceuticals, Inc. Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Pre-Menstrual Syndrome Introduction
  • 12.8.4 Pherin Pharmaceuticals, Inc. Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.8.5 Pherin Pharmaceuticals, Inc. Recent Development
• 12.9 Umecrine Mood AB
  • 12.9.1 Umecrine Mood AB Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Pre-Menstrual Syndrome Introduction
  • 12.9.4 Umecrine Mood AB Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.9.5 Umecrine Mood AB Recent Development
• 12.10 Novartis AG
  • 12.10.1 Novartis AG Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Pre-Menstrual Syndrome Introduction
  • 12.10.4 Novartis AG Revenue in Pre-Menstrual Syndrome Business (2014-2019)
  • 12.10.5 Novartis AG Recent Development
• 12.11 GlaxoSmithKline Plc

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer